Katherine Y. Look

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Medicine, Gynecology, Oncology +16

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 679 citations · Full text

Medicine, Gynecology, Oncology +6

Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

Gini F. Fleming, Virginia L. Brunetto, David Cella et al. · Journal of Clinical Oncology · 2004 · 567 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study

Jeffrey G. Bell, Mark F. Brady, Robert C. Young et al. · Gynecologic Oncology · 2006 · 308 citations

Medicine, Gynecology, Oncology +13

Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers

Paul J. Goodfellow, Barbara M. Buttin, Thomas J. Herzog et al. · Proceedings of the National Academy of Sciences · 2003 · 238 citations

Medicine, Genetics, Oncology +17